Peripheral neuropathy related to chemotherapy

Semin Oncol Nurs. 2007 Aug;23(3):162-73. doi: 10.1016/j.soncn.2007.05.001.

Abstract

Objectives: To review the evidence base for prevention and intervention of chemotherapy-induced peripheral neuropathy (PN).

Data sources: Medical and nursing literature.

Conclusion: Many small studies that reported positive findings have either not been validated in large prospective, randomized controlled trials (RCT), or have not been further studied. Prevention strategies based on RCTs include the use of xaliproden to reduce the incidence of grade 3 PN in patients receiving oxaliplatin-based regimens, and dose reduction or interruption until recovery. There are gaps in the literature of nurse-sensitive outcome studies for nursing assessment and intervention

Implications for nursing practice: Nurses need to be knowledgeable about the evidence, or lack of it, on strategies to prevent and manage chemotherapy-induced PN. Nurses also need to measure the effectiveness of interventions for PN, such as exercise, patient teaching about self-care strategies, and develop and/or participate in well-designed intervention studies regarding the prevention and management of PN.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Humans
  • Peripheral Nervous System Diseases / chemically induced*
  • Peripheral Nervous System Diseases / nursing
  • Peripheral Nervous System Diseases / prevention & control

Substances

  • Antineoplastic Agents